MDEA · EVE · N-Ethyl-MDA · 3,4-Methylenedioxy-N-ethylamphetamine
A stirred suspension of 4.8 g LAH in 400 mL anhydrous THF was brought up to a reflux, and then treated with a solution of 5.0 g of the impure N-acetyl-3,4-methylenedioxyamphetamine in 20 mL anhydrous THF. Reflux conditions were maintained for 3 days, and then after cooling in an ice bath, the excess hydride was destroyed with the careful addition of H2O. The 4.8 mL H2O (in a little THF) was followed with 4.8 mL of 15% NaOH, and finally an additional 15 mL H2O. The white, granular, basic mass of inorganic salts was removed by filtration, the filter cake washed with additional THF, and the combined filtrate and washings stripped of solvent under vacuum. The residue was dissolved in 20 mL IPA, made acidic with 40 drops of concentrated HCl, and diluted with 150 mL anhydrous Et2O. The crystalline product was removed by filtration, washed with 80% Et2O (containing IPA) followed by Et2O itself, and then air dried to provide 3.0 g of 3,4-methylenedioxy-N-ethylamphetamine hydrochloride (MDE) as fine white crystals with a mp of 198–199 °C.
(from 3,4-methylenedioxyphenylacetone with aluminum amalgam) To 40 g of thin aluminum foil cut in 1 inch squares (in a 2 L wide mouth Erlenmeyer flask) there was added 1400 mL H2O containing 1 g mercuric chloride. Amalgamation was allowed to proceed until there was the evolution of fine bubbles, the formation of a light grey precipitate, and the appearance of occasional silvery spots on the surface of the aluminum. This takes between 15 and 30 min depending on the freshness of the surfaces and the temperature of the H2O. The H2O was removed by decantation, and the aluminum was washed with 2×1400 mL of fresh H2O. The residual H2O was removed as thoroughly as possible by shaking, and there was added, in succession and with swirling, 72.5 g ethylamine hydrochloride dissolved in 60 mL warm H2O, 180 mL IPA, 145 mL 25% NaOH, 53 g 3,4-methylenedioxyphenylacetone (see under
(from 3,4-methylenedioxyphenylacetone with NaBH3CN) To a well stirred solution of 31.0 g ethylamine hydrochloride in 110 mL MeOH there was added 6.6 g of 3,4-methylenedioxyphenylacetone (see under
DOSAGE: 100–200 mg.
DURATION: 3–5 h.
QUALITATIVE COMMENTS: (with 100 mg) “There was a warm light all about me. And a gentle, almost alcohol-like, intoxication. The drug seems to change my state of awareness, but it does nothing else. The world is as intense or as dull as I choose to make it. At the 1.5 hour point I was clearly dropping, and an hour later yet, completely without residue.”
(with 160 mg) “The first effects were felt in forty minutes and I seemed to be completely there by the end of that first hour. There was an initial slightly dizzy intoxication, and then I felt very nice. A good intoxication, with maybe a little motor incoordination. There was absolutely no appetite at all. The next morning there was still some feeling of elation but I was still very relaxed. High marks for the quality of the experience.”
(with 160 mg) “Overall this was a wonderful experience. I felt that the effect was stronger and smoother than
(with 160 mg) “I was hard hit, to the extent that there was difficulty in verbalizing and following other people’s thoughts. I entered the experience with some cold symptoms, and my sore throat disappeared. I felt quite intoxicated and tranquilized.”
(with 200 mg) “Very stoned. There was some nausea in the beginning of the experience. As it developed I found it very difficult to concentrate on what I was thinking or saying simply due to the extraordinary nature of coming on to this material. There is noticeable jaw-clenching and rice crispies in the ears. This is a meditative material not unlike
EXTENSIONS AND COMMENTARY: This immediate homologue of
The effects of MDE are similar in many ways to those of
There are only two ways in which two drugs can interact to produce a result that is not obvious from the summing of their individual actions. One is the process of synergism, where two active materials are allowed to interact within a single individual and at one time, and the consequence of this interaction is different than that which would have been expected. The other is the process of potentiation, where only one drug is active, but the presence of the second (and inactive) drug enhances the observed action of the first. MDE seems to fall in the first category.
The “piggy-back” or “window exploitation” studes were first discovered and explored with MDE, and have subsequently been extended most successfully with
With the placement of
I have been told of an analogue of MDE that has been synthesized, and explored by the researcher who synthesized it. It contains the N-trifluoroethyl group common to several pharmaceuticals such as Quazepam. The analogue is
Another direction that has been used to homologate the
13 May 2016 · · Isomer Design
About PiHKAL · info
This version of Book II of PiHKAL is based on the Erowid online version, originally transcribed by Simson Garfinkle and converted into HTML by Lamont Granquist. I drew also on “Tyrone Slothrop’s” (Unfinished) Review of PIHKAL to enumerate the many analogues mentioned in PiHKAL but not described at length. Many, many others have since been added.
I have tried here to expunge any artifacts introduced by the earlier transcriptions and restore the typographic niceties found in the printed edition. I’ve also made minor changes to some chemical names in line with current nomenclature practice. Typically the change is little more than expanding a prefix or setting it in italics. The history page has further details.
“At the present time, restrictive laws are in force in the United States and it is very difficult for researchers to abide by the regulations which govern efforts to obtain legal approval to do work with these compounds in human beings.“No one who is lacking legal authorization should attempt the synthesis of any of the compounds described in these files, with the intent to give them to man. To do so is to risk legal action which might lead to the tragic ruination of a life. It should also be noted that any person anywhere who experiments on himself, or on another human being, with any of the drugs described herein, without being familiar with that drug’s action and aware of the physical and/or mental disturbance or harm it might cause, is acting irresponsibly and immorally, whether or not he is doing so within the bounds of the law.”
The copyright for Book I of PiHKAL has been reserved in all forms and it may not be distributed. Book II of PiHKAL may be distributed for non-commercial reproduction provided that the introductory information, copyright notice, cautionary notice and ordering information remain attached.
PiHKAL is the extraordinary record of the authors’ years exploring the chemistry and transformational power of phenethylamines. This book belongs in the library of anyone seeking a rational, enlightened and candid perspective on psychedelic drugs.
Though Sasha and Ann have put Book II of PiHKAL in the public domain, available to anyone, I strongly encourage you to buy a copy. We owe them — and there’s still nothing quite like holding a real book in your hands.
PiHKAL (ISBN 0-9630096-0-5) is available for US$24.50 (plus $10 domestic first-class shipping) from Transform Press.Transform Press,
Berkeley, CA 94701
510 · 934 · 4930 (voice)
510 · 934 · 5999 (fax)